Yazarlar : Valdas P, Ausra J, Reda M, Zvirblis T, Laimonas G.

Yayın : Leuk Lymphoma.

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/21955292

Konu : Myelom

Literatür İçeriği :  

Abstract

Abstract Pretreatment detection of peripheral blood malignant circulating plasma cells (CPC) has been shown to be of negative prognostic value in multiple myeloma (MM). We hypothesized that assessment of CPC kinetics in response to one therapy cycle using six-color flow cytometry could be helpful in the early detection of MM refractoriness to treatment. 42 patients with refractory or relapsed (RR) MM were enrolled. Median TTP of 51 day and median overall survival (OS) of 308 days was shortest in patients whose aCPCs did not decrease after one therapy cycle compared to patients with decreasing (median TTP 258 days and OS 856 days) or undetectable (median TTP 581 days and OS 1006 days) aCPCs (p < 0.001 and p = 0.007 for TTP and OS, respectively). Nonreduction of aCPCs in RR MM patients after the first cycle of therapy may be useful in early identification of patients resistant to given therapy.

Literatür Arşivi